Samuel Kintz - Feb 13, 2024 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Ben Hohl, by power of attorney
Stock symbol
ELVN
Transactions as of
Feb 13, 2024
Transactions value $
$0
Form type
4
Date filed
2/15/2024, 08:56 PM
Previous filing
Jan 29, 2024
Next filing
Feb 28, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Award $0 +410K $0.00 410K Feb 13, 2024 Common Stock 410K $14.85 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4th of the shares subject to the option will vest on February 13, 2025 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.